A trial of a vaccine called rindopepimut for glioblastoma (ACT IV)

This trial is looking at a new treatment vaccine called rindopepimut alongside temozolomide for people with a type of brain tumour called glioblastoma.

If you are diagnosed with a glioblastoma, you usually have surgery followed by radiotherapy and chemotherapy at the same time. Temozolomide is a chemotherapy drug that doctors often use. It is a standard treatment. After you finish radiotherapy, you may have temozolomide on its own. This is called adjuvant or maintenance treatment.

In this trial, researchers are looking at a new treatment vaccine called rindopepimut alongside temozolomide. Rindopepimut (also known as CDX-110) is a type of biological therapy called a cancer vaccine.

Between a quarter and a third of all glioblastomas may contain a particular protein called EGFRvIII. Rindopepimut is being tested to see if it can train the immune system to recognise this protein and kill the glioblastoma cells. Everybody taking part in this trial will have a test first to confirm if their glioblastoma contains the protein. The aim of the trial is to see if rindopepimut alongside temozolomide helps this group of people. The researchers want to

• Find out if rindopepimut helps to shrink the glioblastoma or delays it starting to grow again

• See if people having this treatment live longer

• Learn more about the side effects and how it affects peoples’ quality of life

• See how rindopepimut affects the immune system